This poster presents Ncardia’s human iPSC-derived seven-tissue safety panel designed to evaluate off-target and on-target off-tumor toxicity of antibody–drug conjugates and other biologics.
The platform combines physiologically relevant human tissues to generate a mechanistically informed safety profile early in development, aligned with the FDA roadmap for biologics safety assessment.
Download it now for a closer look at:
A seven-tissue iPSC-derived screening panel representing heart, CNS, vascular endothelium, lung, liver, skin, and intestinal epithelium for evaluating tissue-specific toxicity risks
In vitro safety profiling of Cetuximab–MMAE, showing strong cytotoxicity in melanocytes consistent with the clinically observed skin toxicity of EGFR-targeting therapies
Real-time cytotoxicity measurements using impedance-based assays to detect dose-dependent tissue responses across multiple human cell types
A human-relevant platform capable of identifying off-target and on-target off-tumor safety liabilities before clinical development
If your ADC program advances to IND, how early are you testing normal human tissues for potential safety liabilities?